Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 4:46 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 2,402 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Dysplasia Mild Clear all
Terminated Not applicable Interventional Results available

Brain Energy Metabolism and Sleep in Adults

NCT03929302
View directory record Official record
Conditions
Alzheimer Disease, Mild Cognitive Impairment, Cognitive Change, Energy Metabolism, Sleep Disturbance
Interventions
MyTAP oral appliance plus mouth shield
Device
Lead sponsor
The University of Texas at Dallas
Other
Eligibility
55 Years to 85 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jun 20, 2024 · Synced Oct 20, 2026, 4:46 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

SimpleC Wellness Platform With Social Robot Interaction (Long-term)

NCT05599503
View directory record Official record
Conditions
Engagement, Patient, Quality of Life, Mood, Aging Well, Cognitive Change, Mild Cognitive Impairment, Cognitive Impairment, Dementia
Interventions
Behavioral Interventions, Robot Interventions
Behavioral
Lead sponsor
SimpleC, LLC
Industry
Eligibility
18 Years and older
Enrollment
63 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
2
States / cities
Athens, Georgia • Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Mar 19, 2024 · Synced Oct 20, 2026, 4:46 PM EDT
Recruiting Not applicable Interventional

Use of Tinted Contact Lenses for Concussion-Related Light Sensitivity

NCT07223086
View directory record Official record
Conditions
Concussion, Mild, Photophobia, Contact Lens
Interventions
Narrow band (tinted) contact lenses, broad band (clear) contact lenses
Device
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jun 11, 2026 · Synced Oct 20, 2026, 4:46 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase I Study to Investigate the Effect of Hepatic Impairment on the PK, Safety, and Tolerability of AZD2693

NCT05919069
View directory record Official record
Conditions
Hepatic Impairment
Interventions
AZD2693
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 75 Years
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
3
States / cities
Rialto, California • Miami Lakes, Florida • Orlando, Florida
Source: ClinicalTrials.gov public record
Updated May 11, 2026 · Synced Oct 20, 2026, 4:46 PM EDT
Terminated Not applicable Interventional

Memory Training and Neural Plasticity

NCT05380739
View directory record Official record
Conditions
Mild Cognitive Impairment
Interventions
Working Memory Training
Behavioral
Lead sponsor
University of Michigan
Other
Eligibility
60 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Oct 20, 2025 · Synced Oct 20, 2026, 4:46 PM EDT
Recruiting Not applicable Interventional

Evaluating Novel Healthcare Approaches to Nurturing and Caring for Hospitalized Elders

NCT05929703
View directory record Official record
Conditions
Delirium, Neurocognitive Disorders, Mild Cognitive Impairment, Alzheimer Disease, Aging, Family Support, Family Members, Caregiver Burden, Implementation Science, Patient Satisfaction
Interventions
HELP, FAM-HELP
Behavioral
Lead sponsor
University of Michigan
Other
Eligibility
70 Years and older
Enrollment
1,900 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
7
States / cities
Orange, California • Portland, Maine • Ann Arbor, Michigan + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 8, 2026 · Synced Oct 20, 2026, 4:46 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Transcranial Magnetic Stimulation for Apathy in Mild Cognitive Impairment

NCT03590327
View directory record Official record
Conditions
Apathy, Mild Cognitive Impairment, Transcranial Magnetic Stimulation, Loneliness, COVID, Neuropsychiatric Symptoms
Interventions
Transcranial Magnetic Stimulation
Device
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
55 Years and older
Enrollment
103 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2024
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated May 22, 2026 · Synced Oct 20, 2026, 4:46 PM EDT
Completed Phase 2 Interventional

A Safety and Tolerability Evaluation of Two 10-Week Dose Regimens of Orally-Administered PF-04494700 in Alzheimer's Patients

NCT00141661
View directory record Official record
Conditions
Alzheimer Disease
Interventions
PF-04494700 - Low Dose Arm, PF-04494700 - High Dose Arm, Placebo Comparator
Drug
Lead sponsor
Pfizer
Industry
Eligibility
50 Years and older
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
12
States / cities
Sun City, Arizona • Fresno, California • San Diego, California + 9 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2009 · Synced Oct 20, 2026, 4:46 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate Pharmacokinetic and Safety Trial of Emraclidine in Participants With Renal Impairment Compared With Participants With Normal Renal Function

NCT05940402
View directory record Official record
Conditions
Renal Impairment
Interventions
Emraclidine
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 75 Years
Enrollment
58 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
5
States / cities
Tustin, California • Miami, Florida • Orlando, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 4, 2025 · Synced Oct 20, 2026, 4:46 PM EDT
Completed Not applicable Interventional

"A Randomized, Controlled, Evaluator-blinded Pilot Study to Evaluate the Effect of Automated Text Message Reminders on Patient Compliance With Topical Medications and Its Efficacy on Skin Disease Control in Adolescents and Adults With Mild to Moderate Acne"

NCT01082523
View directory record Official record
Conditions
Acne, Patient Compliance
Interventions
Text message reminders
Other
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
12 Years to 30 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
2
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Sep 17, 2019 · Synced Oct 20, 2026, 4:46 PM EDT
Completed Phase 1 Interventional

Open Label Pharmacokinetic Study of SAR302503 in Subjects With Hepatic Impairment

NCT01762462
View directory record Official record
Conditions
Hepatic Impairment
Interventions
SAR302503
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 75 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
3
States / cities
Miami, Florida • Orlando, Florida • Knoxville, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 5, 2025 · Synced Oct 20, 2026, 4:46 PM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of Secukinumab in Mild Psoriasis

NCT03131570
View directory record Official record
Conditions
Psoriasis
Interventions
Secukinumab, Placebo followed by Secukinumab
Drug
Lead sponsor
James G. Krueger, MD, PhD
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 21, 2022 · Synced Oct 20, 2026, 4:46 PM EDT
Completed Phase 1 Interventional

Short Term Efficacy and Safety of Perispinal Administration of Etanercept in Mild to Moderate Alzheimer's Disease

NCT01716637
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Etanercept, Curcum.Luteol.Theaflav.Lip.Acid,FishOil,Quercet.,Resveratr.
Biological · Dietary Supplement
Lead sponsor
Life Extension Foundation Inc.
Other
Eligibility
60 Years to 85 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
2
States / cities
Coral Springs, Florida • Delray Beach, Florida
Source: ClinicalTrials.gov public record
Updated May 12, 2016 · Synced Oct 20, 2026, 4:46 PM EDT
Completed Phase 2 Interventional Results available

Evaluation of Doxycycline Verses Placebo for the Treatment of Severe Nonproliferative or Mild or Moderate Proliferative Diabetic Retinopathy

NCT00511875
View directory record Official record
Conditions
Diabetic Retinopathy
Interventions
doxycycline monohydrate, placebo
Drug
Lead sponsor
Thomas Gardner
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 2, 2018 · Synced Oct 20, 2026, 4:46 PM EDT
Completed No phase listed Observational

Visual Dysfunction in Mild Traumatic Brain Injury (MTBI): A Comparison Group Study

NCT00671450
View directory record Official record
Conditions
Post-Traumatic Stress Disorder
Interventions
Not listed
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
19 Years to 39 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Jan 28, 2013 · Synced Oct 20, 2026, 4:46 PM EDT
Completed Phase 2 Interventional

Open-Label Study Evaluating Synera® in the Treatment of Patients With Carpal Tunnel Syndrome

NCT00991068
View directory record Official record
Conditions
Carpal Tunnel Syndrome
Interventions
Synera (lidocaine 70 mg and tetracaine 70 mg) topical patch
Drug
Lead sponsor
ZARS Pharma Inc.
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Mar 16, 2012 · Synced Oct 20, 2026, 4:46 PM EDT
Completed Not applicable Interventional

Evaluation of the Impact of the HL Natural, Inc. Tension Relief Product

NCT04091555
View directory record Official record
Conditions
Tension, Headache
Interventions
HLNatural Tension
Dietary Supplement
Lead sponsor
Hawthorne Effect Inc.
Other
Eligibility
18 Years and older
Enrollment
117 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Lafayette, California
Source: ClinicalTrials.gov public record
Updated Nov 15, 2021 · Synced Oct 20, 2026, 4:46 PM EDT
Recruiting Not applicable Interventional

Wearable Technology to Characterize and Treat mTBI Subtypes: Biofeedback-Based Precision Rehabilitation

NCT06381674
View directory record Official record
Conditions
Mild Traumatic Brain Injury, Concussion, Rehabilitation, Balance Impairment
Interventions
Vestibular therapy for mTBI augmented with audio and visual real-time biofeedback, Vestibular therapy for mTBI
Other
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years to 60 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
3
States / cities
Portland, Oregon • San Antonio, Texas • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Oct 14, 2025 · Synced Oct 20, 2026, 4:46 PM EDT
Completed Not applicable Interventional Results available

Open-label, Prospective Evaluation of the Ulthera® System for Lifting Submental (Under the Chin) and Neck Tissue in Chinese Patients

NCT03351335
View directory record Official record
Conditions
Mild to Moderate Skin Laxity Under the Chin, Mild to Moderate Skin Laxity on Neck
Interventions
Microfocused ultrasound with visualization
Device
Lead sponsor
Merz North America, Inc.
Industry
Eligibility
35 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
7
States / cities
Los Gatos, California • San Diego, California • Vista, California + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 28, 2019 · Synced Oct 20, 2026, 4:46 PM EDT
Completed Phase 2 Interventional

Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors

NCT01549834
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
ABT-126, placebo
Drug
Lead sponsor
AbbVie (prior sponsor, Abbott)
Industry
Eligibility
55 Years to 90 Years
Enrollment
434 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
11
States / cities
Fresno, California • Long Beach, California • San Francisco, California + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 31, 2014 · Synced Oct 20, 2026, 4:46 PM EDT
Recruiting Phase 2 Interventional

Sleep Healthy Using the Internet Mitigating Insomnia to Address Neurocognitive Difficulties (SHUTi MIND)

NCT05565833
View directory record Official record
Conditions
Insomnia, Cognitive Dysfunction, Mild Cognitive Impairment, Sleep Initiation and Maintenance Disorders, Sleep Disorders, Intrinsic, Dyssomnias, Sleep Wake Disorders, Nervous System Diseases, Alzheimer Disease
Interventions
SHUTi OASIS, Patient Education
Behavioral · Other
Lead sponsor
University of Virginia
Other
Eligibility
65 Years and older
Enrollment
144 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated May 8, 2024 · Synced Oct 20, 2026, 4:46 PM EDT
Recruiting Phase 2 Interventional

Confirmatory Clinical Study in Active Ulcerative Colitis

NCT07296315
View directory record Official record
Conditions
Colitis, Ulcerative
Interventions
Low-dose MH002, High-dose MH002, Placebo
Drug
Lead sponsor
MRM Health NV
Industry
Eligibility
16 Years and older
Enrollment
204 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
6
States / cities
Miami, Florida • Orlando, Florida • Palmetto Bay, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 30, 2026 · Synced Oct 20, 2026, 4:46 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Integrated Eye Tracking and Neural Monitoring for TBI: Optimization

NCT03451058
View directory record Official record
Conditions
Traumatic Brain Injury
Interventions
Not listed
Lead sponsor
United States Naval Medical Center, San Diego
Federal
Eligibility
18 Years to 55 Years
Enrollment
138 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2021
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Feb 11, 2022 · Synced Oct 20, 2026, 4:46 PM EDT
Completed Phase 2 Interventional Results available

Study of Daratumumab in Patients With Mild to Moderate Alzheimer's Disease

NCT04070378
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Daratumumab Injection
Drug
Lead sponsor
Marc L Gordon, MD
Other
Eligibility
55 Years to 85 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Manhasset, New York
Source: ClinicalTrials.gov public record
Updated Nov 14, 2025 · Synced Oct 20, 2026, 4:46 PM EDT